Savara Shares Fall Pre-Bell After Company Says FDA Will Not Meet PDUFA Target Action Date for Rare Lung Disease Treatment

MT Newswires Live
Nov 20

Savara (SVRA) shares fell more than 21% in Friday premarket activity after the US Food and Drug Administration communicated that it will not meet the target action date of its biologics license application for molgramostim inhalation solution, which is intended for autoimmune pulmonary alveolar proteinosis, a rare lung disorder.

The supposed Prescription Drug User Fee Act, or PDUFA, target action date of the application was Nov. 22.

The company said the review of its application is ongoing and no revised action date has been provided by the FDA.

Price: 4.10, Change: -1.11, Percent Change: -21.31

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10